NCT00217971

Dronabinol Treatment for Marijuana Addiction

A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 156 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine if dronabinol decreases the symptoms of marijuana addiction and withdrawal.

Detailed description

Marijuana addiction is associated with significant withdrawal symptoms, including anxiety, irritability, bodily discomfort, and insomnia. The purpose of this study is to determine the effectiveness of dronabinol in reducing withdrawal symptoms. During this twelve-week, double-blind, placebo-controlled study, study visits will occur twice each week. During study visits, participants will receive either placebo or medication. Throughout the study, all participants will receive individualized psychotherapy sessions. At each study visit, vital signs, self-report ratings, and urine samples will be collected. Participants will have a follow-up evaluation at month 6.

Conditions

• Marijuana Abuse

Interventions

Type	Name	Description
DRUG	Dronabinol	Dronabinol
DRUG	Placebo	placebo

Timeline

• Start date: 2005-03-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2005-09-22
• Last updated: 2019-04-24
• Results posted: 2011-11-01

Locations

1 site across 1 country: United States